Coriolis Pharma, RheaVita Partner on Freeze-Drying Technology

Coriolis Pharma, a globally operating service provider in formulation research and development of biopharmaceuticals, and RheaVita, a supplier of continuous freeze-drying technology for biopharmaceuticals, have joined forces to advance the novel technology for drug product development of biologics, in particular novel modalities.

RheaVita’s continuous freeze-drying technology integrates all traditional freeze-drying steps into a continuous production line. According to the company, this enables pharma companies to achieve rapid product and process development, as well as highly flexible and efficient production cycles with 100% controlled product quality. The technology enables both high-volume centralized manufacturing and low-volume, high-value decentralized manufacturing, making it ideal for innovative biologics such as gene therapy, RNA-based therapies, antibodies, vaccines, as well as precision medicine and orphan drug manufacturing.

Coriolis will offer the SVU technology alongside with other technologies and methods for its client formulation development projects. Coriolis provides expertise in formulation development, lyophilization and analytics for a wide range of molecule classes, which is brought to bear in the evaluation of the SVU technology.

Under the collaboration, RheaVita will benefit from Coriolis as a multiplier to enable the validation of the technology for different types of drug products and a wider range of applications. In the long run, the scientific exchange between the two companies will allow the technology to be extended to new molecule classes.

“RheaVita’s SVU technology is the ideal supplement for our existing methods in the field of lyophilization process development”, said Michael Wiggenhorn, founder, and board director at Coriolis Pharma. “Through our service model, our clients will get the chance to test and evaluate the new technology by a formulation development expert for their own drug development strategy. “

“Coriolis’ extensive scientific expertise with various molecule categories and their deep expertise in formulation development have convinced us, that we have found the ideal partner to expand the accessibility of our technology to a broader audience in the future,” said Thomas De Beer, CEO at RheaVita.